Robert Nelsen has served as a member of our Board since October 2018. Mr. Nelsen is a co-founder and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 30 biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology, biopharmaceutical, and healthcare companies, including Brii Biosciences Limited, Hua Medicine, where he serves as Chairman, Lyell Immunopharma, Inc., Prime Medicine, Inc., and Vir Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc., Bellerophon Therapeutics, Inc., Denali Therapeutics Inc., Fate Therapeutics, Inc., Gossamer Bio, Inc., Illumina, Inc., Juno Therapeutics, Inc., Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as a Trustee of the Fred Hutchinson Cancer Center and the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound.
What is Robert Nelsen's net worth?
The estimated net worth of Robert Nelsen is at least $16.58 million as of February 15th, 2024. Nelsen owns 3,200,000 shares of Sana Biotechnology stock worth more than $16,576,000 as of December 5th. This net worth estimate does not reflect any other investments that Nelsen may own. Learn More about Robert Nelsen's net worth.
How do I contact Robert Nelsen?
Has Robert Nelsen been buying or selling shares of Sana Biotechnology?
Robert Nelsen has not been actively trading shares of Sana Biotechnology during the last quarter. Most recently, on Thursday, February 8th, Robert Nelsen bought 1,818,181 shares of Sana Biotechnology stock. The stock was acquired at an average cost of $5.50 per share, with a total value of $9,999,995.50. Following the completion of the transaction, the director now directly owns 12,446,022 shares of the company's stock, valued at $68,453,121. Learn More on Robert Nelsen's trading history.
Who are Sana Biotechnology's active insiders?
Are insiders buying or selling shares of Sana Biotechnology?
During the last year, insiders at the sold shares 1 times. They sold a total of 290,912 shares worth more than $1,888,018.88. The most recent insider tranaction occured on January, 8th when insider Fmr Llc sold 290,912 shares worth more than $1,888,018.88. Insiders at Sana Biotechnology own 30.1% of the company.
Learn More about insider trades at Sana Biotechnology. Information on this page was last updated on 1/8/2025.
